Musculoskeletal Supplement Musculoskeletal Cardiovascular Immune

Urolithin A (Mitopure)

yoor-oh-LITH-in A

Formula C13H8O4 MW 228.2 g/mol PubChem CID 5488186 →

IUPAC 3,8-dihydroxybenzo[c]chromen-6-one

SMILES C1=CC2=C(C=C1O)C(=O)OC3=CC(=CC=C32)O

2D structure

Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

Urolithin A is the cleanest evidence story in the supplement space. Timeline/Amazentis has published six human clinical trials showing improved mitochondrial function and muscle endurance. It holds GRAS status, Informed Sport certification, and has the strongest regulatory profile of any longevity supplement.

However, the trials are relatively small (40-100 participants), short-term (4-6 months), and use surrogate biomarkers rather than hard clinical endpoints. No mortality or major morbidity data exists. The C+ grade reflects real but preliminary evidence.

Safety Considerations

Generally well-tolerated. GRAS status. No significant adverse events in published trials. Pregnant/nursing should avoid due to insufficient data.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Urolithin A (Mitopure)

🔒

2 commercial products are listed for this molecule. Create a free account to see them, with each product's dose next to the evidence dose.

Create a free account

Regulatory Intelligence

🔒

Subscribe to access FDA enforcement history, third-party verification status, and regulatory risk assessment.

This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.